Chiasma, Inc.

    Jurisdiction
    United States
    LEI
    549300PP2WZZEZZ6XS69
    ISIN
    US16706W1027 (CHMA)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    3 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    2 / 7

    Profile

    Chiasma, Inc., a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €2.60M
    Gross margin
    95.8%
    EBIT
    -€62.62M
    EBIT margin
    -2,408.6%
    Net income
    -€77.17M
    Net margin
    -2,968.3%

    Statement period: - (published )

    Dividends

    No dividend payouts

    Earnings Calls

    Latest earnings call: March 4, 2021

    Add to watchlist

    Notifications